Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
oral GLP-1
Advertisement
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Novo Nordisk Secures EU Approval for Oral Wegovy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Advertisements
Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Lilly’s Foundayo Shows Strong Weight Loss in Seniors
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
Advertisement
